Repligen Completes Patient Enrollment In Phase 2b Clinical Trial Of RG2417 For Bipolar … - RTT News
(RTTNews) - Repligen Corp. (RGEN: News ) said it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. According to the company, the study is a double-blind …